Quest Diagnostics Incorporated’s Stock Price Soars to $136.70, Marking a Robust 5.08% Uptick

Quest Diagnostics Incorporated (DGX)

136.70 USD +6.61 (+5.08%) Volume: 2.09M

Quest Diagnostics Incorporated’s stock price surges to $136.70, a significant +5.08% increase in this trading session with a robust trading volume of 2.09M, despite a slight year-to-date decline of -0.86%, showcasing its resilient market performance.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics (DGX) has seen a surge in its stock price following a series of positive financial announcements. The firm’s Q1 2024 earnings topped estimates, despite a decrease in margins, with profits and revenue for the year projected to be higher due to strong demand. Sales in Q1 increased for the first time since the pandemic’s peak, leading to a boost in the company’s adjusted EPS view for 2024. Moreover, Quest Diagnostics has added p-tau217 blood biomarker testing to its suite of services, further expanding its Alzheimer’s test portfolio.

Quest Diagnostics Incorporated on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish report on Quest Diagnostics, focusing on the company’s continued investment in new technologies and automated solutions. The report highlights Quest Diagnostics Incorporated’s fourth quarter and full year 2023 earnings call, which emphasized the company’s strategy to drive top-line growth and increase profitability. In 2023, the company achieved 7% revenue growth in its base business and met its earnings commitments as it moved away from COVID-19 testing. Baptista Research is evaluating various factors that could impact the company’s stock price in the near future and is conducting an independent valuation using a Discounted Cash Flow (DCF) methodology.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics, a company that provides diagnostic testing and services, has received high scores in Dividend and Value, indicating a positive long-term outlook. With a strong focus on providing dividends to shareholders and being perceived as a valuable investment, Quest Diagnostics seems to be a stable choice for investors looking for reliable returns. However, the company scored lower in Resilience and Growth, suggesting potential challenges in adapting to market changes and achieving significant growth in the future.

Despite facing some hurdles in terms of Resilience and Growth, Quest Diagnostics shows promising Momentum with a score of 4. This indicates that the company is gaining traction in the market and is moving in a positive direction. Overall, Quest Diagnostics‘ Smart Scores paint a picture of a company with solid fundamentals and a strong dividend track record, but with room for improvement in terms of resilience and growth strategies in the long run.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma